Adverse Effects of Risperidone on Spatial Working Memory in First-Episode Schizophrenia

James L. Reilly, PhD; Margret S. H. Harris, MA; Matcheri S. Keshavan, MD; John A. Sweeney, PhD

Context: Working memory impairments are a central neurocognitive feature of schizophrenia. The nature of these impairments early in the course of illness and the impact of antipsychotic drug treatment on these deficits are not well understood. The oculomotor delayed response task is a translational spatial working memory paradigm used to characterize the neurophysiologic and neurochemical aspects of working memory in the primate brain.

Objective: To examine oculomotor delayed response task performance in patients with first-episode schizophrenia before and after antipsychotic drug treatment.

Design, Setting, and Participants: Twenty-five antipsychotic drug-naive, acutely ill patients with first-episode schizophrenia performed an oculomotor delayed response task at baseline before any drug treatment and again after 6 weeks of risperidone treatment. Twenty-five matched healthy controls were studied in parallel.

Main Outcome Measure: Accuracy for remembered spatial locations on an oculomotor delayed response task.

Results: Before treatment, patients demonstrated baseline impairment in the ability to maintain spatial location information in working memory at longer delay periods (8 seconds), when maintenance demands on working memory were greatest. After 6 weeks of risperidone treatment and significant clinical improvement, this pretreatment impairment worsened such that patients were uniformly impaired across all delay periods (1-8 seconds). This occurred in the absence of any generalized adverse effect on oculomotor systems or significant extrapyramidal adverse effects.

Conclusions: Deficits in the maintenance of spatial information in working memory are present early in the course of illness. Risperidone treatment exacerbated these deficits, perhaps by impairing the encoding of information into working memory. Studies with nonhuman primates performing oculomotor delayed response tasks suggest that the apparent adverse effect of risperidone might result from treatment-related changes in modulatory functions of prefrontal D1 receptor systems.

Arch Gen Psychiatry. 2006;63:1189-1197
Table. Demographic and Clinical Characteristics of Patients With Schizophrenia and Controls

<table>
<thead>
<tr>
<th></th>
<th>Controls (n = 25)</th>
<th>Patients (n = 25)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline demographics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, mean (SD), y*</td>
<td>25.1 (5.2)</td>
<td>24.6 (6.8)</td>
<td>&gt;.76</td>
</tr>
<tr>
<td>IQ, mean (SD)*</td>
<td>98.2 (8.9)</td>
<td>95.4 (10.0)</td>
<td>&gt;.29</td>
</tr>
<tr>
<td>Parental SES, mean (SD)*</td>
<td>2.2 (0.8)</td>
<td>2.7 (1.3)</td>
<td>&gt;.24</td>
</tr>
<tr>
<td>Sex, M/F, No.‡</td>
<td>17/8</td>
<td>18/7</td>
<td>&gt;.76</td>
</tr>
<tr>
<td>Handedness, right/left, No.‡</td>
<td>23/2</td>
<td>24/1</td>
<td>&gt;.55</td>
</tr>
<tr>
<td>Clinical ratings and medication, mean (SD)§</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BPRS score</td>
<td>NA</td>
<td>51.4 (8.5)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>SANS score</td>
<td>NA</td>
<td>15.0 (2.5)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>SAPS score</td>
<td>NA</td>
<td>9.9 (3.2)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>HAM-D score</td>
<td>NA</td>
<td>21.0 (11.9)</td>
<td>&gt;.06</td>
</tr>
<tr>
<td>Risperidone, mg/d</td>
<td>NA</td>
<td>0.0 (4.1)</td>
<td>&gt;.50</td>
</tr>
<tr>
<td>EPSE scale score</td>
<td>NA</td>
<td>3.9 (4.5)</td>
<td>&gt;.50</td>
</tr>
<tr>
<td>Risperidone, mg/d</td>
<td>NA</td>
<td>0.0 (4.1)</td>
<td>&gt;.50</td>
</tr>
<tr>
<td>EPSE scale score</td>
<td>NA</td>
<td>3.9 (4.5)</td>
<td>&gt;.50</td>
</tr>
</tbody>
</table>

Abbreviations: BPRS, Brief Psychiatric Rating Scale; EPSE, Extrapyramidal Side Effects; HAM-D, Hamilton Depression Rating Scale (24 items); NA, not applicable; SANS, Schedule for the Assessment of Negative Symptoms; SAPS, Schedule for the Assessment of Positive Symptoms; SES, socioeconomic status.

*For age and IQ (Ammons Quick Test®), P Values reflect the significance level for independent-sample t tests.
†The P value for parental SES (Hollingshead®) represents the significance level for a Mann-Whitney test.
‡P Values for sex and handedness (Edinburgh Handedness Questionnaire®) reflect the significance level for a χ² test.
§P Values for clinical ratings reflect significance levels for paired-sample t tests.

course of illness are not well characterized. More important, how these impairments are affected by antipsychotic drug treatments has yet to be directly investigated. Studies documenting impaired ODR task performance among patients with schizophrenia have typically used medications (which may disentangle disease and medication effects) in an uncontrolled fashion. The few studies of untreated or never-treated patients are limited by the use of cross-sectional rather than longitudinal designs and by treatment with heterogeneous antipsychotic medications and adjunctive agents. Also, the effects of delay period duration have not been investigated systematically in these studies, so it remains unclear whether performance deficits reflect a problem initially encoding information into working memory or a faster rate of information decay once information is encoded.

In the present study, treatment-naïve patients with first-episode schizophrenia performed an ODR task at baseline and again after 6 weeks of risperidone treatment. Matched controls were studied during a similar time frame. The delay period during which information was remembered varied between 1 and 8 seconds to determine whether patient performance changed as a function of increased temporal maintenance demands and whether treatment differentially affected performance across delay period durations. Subsets of both groups were available for additional assessments at 26- and 52-week follow-up.

**METHODS**

**PARTICIPANTS**

Twenty-five antipsychotic drug–naïve patients (7 women and 18 men) met criteria for schizophrenia according to the Structured Clinical Interview for DSM-III-R and additional information reviewed at consensus diagnosis meetings. Patients had experienced psychotic symptoms on average for 1 year before entering the study (median duration of untreated illness, 11.8 months). Twenty-five healthy individuals (8 women and 17 men) without any Axis I disorders according to the Structured Clinical Interview for DSM-III-R and recruited from the community. Groups were matched for age, IQ, sex, parental socioeconomic status, and handedness (Table). All the participants met the following criteria: (1) age 18 to 49 years, (2) no systemic or neurologic disease, (3) no electroconvulsive therapy, (4) no history of head trauma, (5) no lifetime history of substance dependence or history of substance abuse within 3 months, (6) no anticonvulsant drug therapy for 1 month or benzodiazepine use for 5 half-lives before testing, and (7) no caffeine intake or cigarette smoking 1 hour before testing. The study was approved by the University of Pittsburgh, Pittsburgh, Pa, institutional review board, and all the participants provided informed consent.

Patients’ baseline ODR studies were conducted before treatment initiation, and follow-up testing occurred on average 6 weeks later. After the baseline evaluation, patients were treated with risperidone (mean ± SD dose = 4.0 ± 1.5 mg). Clinical psychologists and psychiatrists blind to ODR task performance completed clinical ratings in parallel with each testing using the Brief Psychiatric Rating Scale, the Scales for the Assessment of Positive and Negative Symptoms, and the 24-item Hamilton Depression Rating Scale (Table). Extrapyramidal adverse effects were modest at the 6-week retesting (Table), but 5 patients were taking low-dose benztropine mesylate (1 or 2 mg).

**ODR TASK**

Participants were tested in a darkened room, and a technician in an adjacent room provided instructions via an intercom. Par-
participants sat facing a circular black arc with a 1-m radius and red light–emitting diodes subtending approximately 0.2° of visual angle in the horizontal plane at eye level. A chin and forehead rest minimized head movement.

Trials began with a brief tone concurrent with the appearance of a central fixation cue (Figure 1). After the participant maintained central fixation for 1.5 seconds, a target appeared for 0.1 seconds unpredictably at 9°, 18°, or 27° of visual angle to the right or left of center. The central cue was sustained during and after this target presentation, and the participant was instructed not to look at the peripheral target but to remember its location. After an unpredictable delay of 1, 2, 4, or 8 seconds, during which central fixation was maintained, the central light was extinguished, cueing the participant to look to the location where the target had appeared. After 1.5 seconds during which the participant could make 1 or more saccadic movements to the remembered location, the correct target location was illuminated for 2 seconds to provide feedback regarding performance accuracy. Twenty-four trials were administered. Eye movements were recorded using electro-oculography. Recordings for each trial were calibrated and measured as described elsewhere.46

Data for each participant were pooled across the 3 peripheral target locations because there were no significant group differences. Repeated-measures analysis of variance was used to compare patients with schizophrenia and controls (between-subject factor), with time (baseline and 6-week follow-up), direction (rightward and leftward trials), and delay period (1, 2, 4, and 8 seconds) as within-subject factors. Effect sizes48 are reported for within- and between-subject effects. Secondary analyses were conducted in the subset of participants available for retesting at 26- and 52-week follow-up to examine the longer-term stability of effects.

**RESULTS**

**ACCURACY OF PRIMARY SACCADES AND FINAL RESTING EYE POSITION**

Gain of patients’ primary saccades to remembered target locations was reduced relative to that of controls ($F_{1,48}=9.75; P=.003$). The magnitude of this group effect was greater at 6-week follow-up than at baseline ($F_{1,48}=9.73; P=.003$), reflecting a significant worsening of patients’ saccade gain after treatment initiation ($t_{24}=4.00; P=.001$; Cohen $d=−0.8$) (Figure 2A). In contrast, there was no significant change in gain over time among controls ($t_{24}=−0.92; P=.37$; Cohen $d=0.2$). Patients also demonstrated progressively poorer gain relative to controls as a function of increased delay period ($F_{3,48}=4.47; P=.008$). At baseline, patients were impaired relative to controls at the 8-second delay period ($t_{24}=3.05; P=.004$; Cohen $d=−0.9$) but not at the shorter delay periods. In contrast, at 6-week follow-up, patients were impaired relative to controls at all delay periods ($P<.01$ for all; Cohen $d≤−0.8$ for all) (Figure 3A). Finally, patients’ primary saccades were less accurate when remembered target locations were to the right of center fixation before and after treatment ($F_{1,48}=5.39; P=.03$) (Figure 4A).

Patients’ performance remained inaccurate compared with that of controls after making additional saccades to correct for any initial motor programming error ($F_{1,48}=7.91; P=.007$). The magnitude of this group difference was greater at 6-week follow-up than at baseline ($F_{1,48}=8.84; P=.005$), reflecting a significant worsening of patients’ error in final resting eye position after treatment initiation ($t_{24}=3.27; P=.003$; Cohen $d=−0.7$).
d = −0.7) (Figure 2B). This change over time was not seen among controls (t_{24} = −0.90; P = .38; Cohen d = 0.2). Patients’ inaccuracy of final resting eye position was also greater than that of controls as a function of increased delay-period duration (F_{3,46} = 3.07; P = .04). Patients’ baseline inaccuracy tended to be greatest at only the 8-second delay period (t_{48} = 1.87; P = .07; Cohen d = −0.5), whereas at 6-week follow-up they differed significantly from controls at all delay periods (P < .02 for all; Cohen d ≤ −0.7 for all) (Figure 3B). Patients’ final resting eye positions were significantly less accurate for locations in the right hemifield compared with controls at both times (F_{1,48} = 7.63; P = .008) (Figure 4B).

**LATENCY AND PROSACCade ERRORS**

Patients were slower than controls in initiating primary saccades to remembered locations (F_{1,48} = 10.24; P = .002). This effect did not change after treatment and did not vary as a function of delay period or response direction.

At each time point, patients committed more prosaccade errors than controls (F_{1,48} = 8.32; P = .01). Both groups showed a comparable decline in errors from baseline (12% for patients vs 8% for controls) to 6-week follow-up (9% for patients vs 3% for controls).

**DURATION OF UNTREATED ILLNESS, CLINICAL RATINGS, AND MEDICATION DOSE**

The duration of untreated psychosis was unrelated to baseline ODR task performance or to changes in performance from baseline to 6-week follow-up. Improvement in clinical symptom ratings was unrelated to changes in ODR task performance from baseline to 6-week follow-up. Extrapyramidal adverse effect ratings and medica-

---

**Figure 3.** Mean gain of primary saccades (A) and error of resting eye position (B) for patients with schizophrenia and controls at baseline and 6-week follow-up. Patients’ accuracy of primary saccades and final resting eye position were decreased only at the longer delay period at the baseline evaluation but across all delay periods at 6-week follow-up compared with controls. *P = .07 and ‡P = .004 for comparisons between patients and controls at baseline. †P < .02 for all comparisons between patients and controls at follow-up. Error bars represent SE.

**Figure 4.** Mean gain of primary saccades (A) and error of resting eye position (B) for patients and controls. Primary saccades and final resting eye positions for target locations in the right hemifield were less accurate for patients than were their responses to left hemifield targets. *P = .05 and †P < .001 for comparisons between patients and controls. Error bars represent SE.
tion doses at 6-week testing were uncorrelated with changes in task performance from baseline to follow-up, although doses were in a relatively narrow range. Exclusion of the 5 patients taking benztropine at 6-week follow-up did not change any findings.

**PERFORMANCE AT THE 26- AND 52-WEEK FOLLOW-UP EVALUATIONS**

The stability of the present findings was examined in secondary analyses of a demographically matched subset of patients (n=13) and controls (n=18) who completed additional follow-up testing at both 26 and 52 weeks. These subgroups did not differ from participants in their respective larger groups in demographic characteristics or task performance at baseline or 6-week follow-up. The patient subgroup did not differ from the complete patient group in clinical ratings at baseline, risperidone dose at 6 weeks, or degree of clinical improvement at 6 weeks. Mean±SD risperidone doses at 26-week (3.6±1.4 mg) and 52-week (3.5±1.6 mg) follow-up were consistent with that at 6 weeks. One patient was taking benztropine (1 mg) at both later time points.

Throughout the 1-year follow-up period, patients remained significantly less accurate than controls in primary saccade gain (F1,29=10.90; P=.003; Cohen d=−0.9) and final resting eye position (F1,29=11.80; P=.002; Cohen d=−1.0). Neither accuracy measure at later time points differed from that at 6 weeks for patients or controls.

**COMMENT**

Antipsychotic drug-naïve patients with first-episode schizophrenia performed an ODR task before and 6 weeks after initiation of risperidone treatment. Before treatment, patients demonstrated impairment in spatial working memory reflected by reduced accuracy of both primary saccade gain and final resting eye position. This impairment was evident only when patients were required to maintain information over the longer delay periods (8 seconds). In contrast, after 6 weeks of risperidone treatment, patients’ baseline impairment was exacerbated such that they were uniformly inaccurate at all delay periods, including very brief delays (1 second). This decline in performance occurred in the absence of significant extrapyramidal adverse effects. Furthermore, these impairments persisted to the 1-year follow-up testing, indicating that patients did not habituate to apparent adverse effects of risperidone. Patients also had longer response latencies and committed more pro-saccade inhibitory errors compared with controls. These performance variables did not change differentially in patients after treatment.

**SPATIAL WORKING MEMORY IMPAIRMENT IN TREATMENT-NAÏVE SCHIZOPHRENIA**

The present study provides new evidence of impairment in spatial working memory during the early phase of untreated schizophrenia. To our knowledge, this is the first study to report a delay-dependent effect among treatment-naïve patients with schizophrenia. This finding suggests that in the acute stages of recent-onset schizophrenia, spatial information is effectively encoded in working memory but that there is a faster rate of decay of spatial information from working memory systems under increased maintenance conditions.

At first glance, that patients in the current study did not demonstrate baseline ODR performance deficits at shorter delay periods may seem contrary to the notion that this is a core disease impairment also present among unaffected first-degree relatives of patients with schizophrenia. Similar to previous investigations with patients, delay period duration was not parametrically varied in these family studies, so relatives’ performance across a range of delay periods is not known. The seminal study by Park et al., which first demonstrated impaired ODR task performance in treated patients with schizophrenia and their relatives, used 10-second delay periods. This period approximates the delay interval at which baseline impairments were detected in the present study. It remains to be determined whether onset of the disorder increases preexisting deficits that are present before treatment initiation. However, the pretreatment findings suggest the possibility that the core spatial working memory deficit in schizophrenia involves a diminished ability to maintain information in working memory over time but not a reduced ability to encode information into working memory stores.

We also found greater impairment in patients when targets were presented in the right hemifield. This effect, which did not change after treatment, is consistent with previously reported findings in which chronically ill, medicated patients with schizophrenia committed more errors when manually identifying the location of remembered targets presented in the right visual field. This laterality bias in the present untreated first-episode sample indicates that the observed hemifield-specific impairment is present at illness onset and thus is not accounted for by effects of treatment or progression of illness. This directional impairment does not reflect a failure to attend and accurately encode information presented in the right hemifield given that a previous study showed comparable accuracy of visually guided saccades made to the left and right visual fields in this sample. In controls performing an ODR task, the contralateral prefrontal cortex has been shown to maintain spatial information of targets presented in the corresponding hemifield across delay periods. Therefore, the present findings suggest greater disturbance in left prefrontal cortex systems, supporting the maintenance of information in spatial working memory in schizophrenia.

On the basis of neurophysiologic studies of nonhuman primates performing the ODR task, pharmacologic investigations of working memory in nonhuman primates and healthy human subjects, and receptor binding studies of medication-free patients with schizophrenia, one possible explanation for the present findings is that patients’ baseline impairment in spatial working memory results from altered D1 receptor activity or distribution in the DLPFC. Studies of monkeys perform-
ing ODR tasks have established that the maintenance of spatial location information in working memory is modulated by D1 receptor activity. Without sufficient D1 stimulation, pyramidal neurons fail to sustain the firing rate needed to retain information in working memory systems over time, and performance deteriorates as a result. Microinjections of D1, but not D2, receptor antagonists into the nonhuman primate DLPFC reduce the accuracy of saccades to remembered targets but have no impact on saccades to visual targets.11 Neurophysiologic studies have established that there is an optimal, but narrow, range of D1 receptor activity of prefrontal neuropsychiatric patients into the nonhuman primate DLPFC reduce the accuracy of saccades to remembered targets but have no impact on saccades to visual targets.51 Neurophysiologic studies have established that there is an optimal, but narrow, range of D1 receptor activity of prefrontal neurons during the delay period when information has to be remembered on the ODR task, with either too much or too little receptor stimulation associated with working memory impairment.24 This “inverted U”-shaped relationship between D1 modulation and working memory is supported by behavioral studies demonstrating that D1 agonists enhance working memory performance in dopamine-deficient monkeys,52,53 whereas D1 antagonists lead to a reversal of impairment in monkeys with experimentally induced dopamine elevation in the DLPFC.54 Evidence of a similar D1 receptor modulation of working memory performance in humans is provided by demonstrations of enhanced working memory after the administration of pergolide mesylate, a combined D1 and D2 agonist, but not the selective D2 agonist bromocriptine mesylate.55

Alterations in prefrontal D1 receptor activation in antipsychotic drug–free patients have been reported in some studies,60–61 although the nature of this alteration is unclear, as both down-regulation and up-regulation have been observed. Using a selective D1 ligand, Abi-Dargham et al58 found increased D1 receptor binding in antipsychotic drug–free patients with schizophrenia. Increased D1 binding in patients predicted impairment on a verbal working memory task, particularly as task demands increased. This increased D1 receptor availability may reflect a compensation, albeit functionally inadequate, for deficient mesocortical dopaminergic input.59 Therefore, it is possible that suboptimal D1 receptor function in the DLPFC could contribute to the poorer pretreatment performance of the patients on the ODR task, particularly when demands on D1 activity to support working memory were greatest (ie, at the longest delay period).

ADVERSE EFFECTS OF RISPERIDONE ON SPATIAL WORKING MEMORY

To our knowledge, this is the first study to document a significant worsening of spatial working memory in patients with schizophrenia after initiating risperidone treatment. After 6 weeks of treatment, patients’ performance declined beyond their initial baseline deficit, and impairment was seen across all delay period durations rather than just in high-maintenance demand conditions. The posttreatment deficits at even 1-second delay periods raise the possibility that encoding processes for working memory were adversely affected by treatment. This effect is striking in that the magnitude of change in patients’ performance from baseline to follow-up is greater than that of the group difference between controls and patients before treatment (Figure 2). Patients’ performance at baseline and 6-week follow-up was highly positively correlated, suggesting that an individual patient’s relative performance within the group is maintained as the group average declines after treatment. This finding points to a consistent treatment effect. Impairments were maintained through 1-year follow-up, indicating that patients did not habituate to apparent treatment effects. The magnitude of the patients’ deficits after treatment is highly consistent with those of a recently published meta-analysis62 of 124 studies examining working memory in schizophrenia, most of which included medicated patients.

Our observation of worsened impairment on an ODR task after treatment initiation in patients with schizophrenia may be best understood in the context of knowledge about risperidone’s pharmacologic properties and recent neurochemical studies with nonhuman primates. In the dopamine system, risperidone strongly antagonizes dopamine D2 and has relatively low affinity for D1 receptors.55 Antagonism of D2 receptors in the PFC does not affect mnemonic performance on this task,56 and thus, risperidone’s effect on D2 receptors is not likely to account for the treatment-related impairment report herein. However, exposure to either typical or atypical antipsychotic medications, including risperidone, induces a robust reduction of D1 receptor expression in the PFC (an approximately two-thirds reduction for risperidone) but not in the striatum.63

Haloperidol administration to monkeys has been shown to result in impaired spatial working memory on an ODR task that was reversed with the administration of a selective full D1 agonist.53 Examination of risperidone’s effects on working memory in monkeys has not been reported, but similar effects are expected given risperidone’s somewhat greater prefrontal D1 down-regulation compared with haloperidol.64 It is thus possible that risperidone’s apparent adverse effect on ODR performance observed in the present study could result, at least in part, from a treatment-related down-regulation of DLPFC D1 receptors. In this case, a reduction in D1 activity associated with risperidone treatment might further compromise a system that at baseline is already dysfunctional in its support of working memory processes.

Pharmacologic effects on neurotransmitter systems other than dopamine, such as antagonism of the serotonin 2A receptor, might also contribute to risperidone’s effects on ODR performance. The role of this receptor in working memory has been examined, albeit to a lesser extent than dopamine receptors. Iontophoresis of a serotonin 2A antagonist on monkey prefrontal neurons, which were neurophysiologically determined to show memory field activity, diminished the activity of these neurons during delay periods of the ODR task.62 This suggests that there may be deleterious effects on working memory associated with serotonin 2A antagonism. It is thus possible that the decline in patient performance after treatment may also result in part from antagonism of serotonin 2A receptors in the prefrontal cortex uniquely or in combination with D1 receptor down-regulation.

Patients’ worsening of performance on the ODR task is not likely to result from generalized adverse treat-
ment effects on oculomotor systems. First, the accuracy of both the primary saccade and final resting eye position declined after treatment, the latter of which relies less on the programming or execution of an initial precise motor response. Second, other saccade parameters, including peak velocity, latency, and duration, were not affected by treatment, and these are typically more sensitive indices of drug-induced changes in oculomotor systems. Third, risperidone doses were not high enough to induce significant extrapyramidal adverse effects that could affect motor programming of saccades. Finally, in a previous study of first-episode patients performing a visually guided saccade task, of which patients in the present study are a smaller subset, we reported a very mild decline in saccade accuracy after starting risperidone treatment. The average decline in memory-guided saccades was 4.5 times greater than that of saccades made in the presence of a visual target. Furthermore, the change in memory-guided saccade accuracy from baseline to 6-week follow-up was not related to changes in visually guided saccades.

The present findings of impaired ODR task performance after risperidone treatment stand in contrast to some recent neuropsychologic studies that reported a modest improvement in working memory after treatment with atypical antipsychotic agents, including risperidone. Several factors may account for this apparent discrepancy. First, studies reporting neuropsychologic improvement with risperidone treatment have not followed treatment-naive patients over time and often report an advantage relative to a conventional antipsychotic drug rather than improvement per se. Second, the absence of a parallel healthy comparison group in larger clinical trials focused on cognitive processes is far more established than that of more complex processes required for most neuropsychologic measures of working memory. It is possible that subcomponents of working memory, and the brain systems that support them, may well be differentially affected by antipsychotic drug treatment. For example, complex problem solving and decision making might be enhanced, whereas the ability to maintain information online might be reduced. Differentiating how treatment affects the various aspects of working memory will require the development and use of paradigms that uniquely tap such sub-processes.

Certain limitations of this study require consideration. Without an untreated patient group followed in parallel with treated patients, the possible role of disease progression as a cause of worsening ODR task performance cannot be logically excluded. However, for several reasons, we believe that this is an unlikely explanation for the current findings. First, it is unlikely that patients who have been ill on average for a year before entering the study would have a sudden, step-wise, and consistent disease-related deterioration precisely at the time when medication treatment is initiated. Second, if the decline in task performance was somehow related to disease progression, then it is likely that the degree of impairment at baseline or the magnitude of decline after treatment would be associated with a greater length of untreated psychosis. This was not the case. Third, in the subset of patients who were available at the 26- and 52-week follow-up evaluations, there was no further deterioration in ODR task performance from the 6-week to the later follow-up visits. Whether the observed effects are specific to risperidone or to classes of antipsychotic drugs cannot be determined based on these findings. This question needs to be addressed in a future study using a randomized clinical trial design with a comparison drug.

We believe that the results of this study underscore the need for greater use and further development of translational tasks and biomarkers as an approach for advancing understanding of treatment effects on neurocognitive systems in schizophrenia. In another study using an antisaccade task with these same patients, we reported improvement after risperidone treatment in the ability to suppress context-inappropriate responses and to more quickly plan and implement behavioral responses. These findings are in contrast to the adverse treatment effects on working memory reported herein. Such a dissociation of risperidone’s effects on “executive” pre-frontal abilities highlights the value of translational approaches that focus on discrete cognitive operations for parsing beneficial and adverse treatment-related changes in neural systems. Such differentiation of treatment effects on cognitive operations is rarely possible with standard neuropsychologic tests. With increased clinical and scientific interest given to developing pharmacologic interventions targeting cognitive symptoms in schizophrenia, neurophysiologic testing that provides a translational bridge between pharmacologic studies with animal models and clinical studies may better clarify the nature of medication effects on cognition and thereby enhance the drug development process.

Submitted for Publication: January 20, 2006; accepted March 13, 2006.

Correspondence: John A. Sweeney, PhD, Center for Cognitive Medicine, University of Illinois at Chicago, 912 S Wood St, Mail Code 913, Chicago, IL 60612 (jsweeney@psych.uic.edu).

Financial Disclosure: None reported.

Funding/Support: This study was supported by grants MH62134, MH45156, MH01433 from the National Institute of Mental Health and grant M01 RR00056 from the National Center for Research Resources/General Clinical Research Center, National Institutes of Health; and the National Alliance for Research on Schizophrenia and Depression.
Acknowledgment: We thank Cameron Carter, MD, Gretchen Haas, PhD, and Debra Montrose, PhD, and the clinical staff of the Pittsburgh Center for the Neuroscience of Mental Disorders for their assistance with diagnostic and psychopathological assessments.

REFERENCES


